Targeting US$610 billion longevity market, biotech firms race to reverse ageing
Biotech firms are actively pursuing the US$610 billion longevity market by developing technologies to reverse or slow the aging process. METiS TechBio CEO Lai Tsai-ta likens aging to software bugs accumulating in cellular genetic code, which he believes can be reprogrammed.

Briefing Summary
AI-generatedBiotech firms are actively pursuing the US$610 billion longevity market by developing technologies to reverse or slow the aging process. METiS TechBio CEO Lai Tsai-ta likens aging to software bugs accumulating in cellular genetic code, which he believes can be reprogrammed. He suggests using artificial intelligence to "read, rewrite and reverse cells." The company's approach could start by repairing immune cells, like T cells, whose declining function in older individuals contributes to increased susceptibility to diseases such as cancer. This research aims to address the fundamental cellular mechanisms of aging.
Article analysis
Model · rule-basedKey claims
4 extractedThe global longevity market is valued at US$610 billion.
Ageing is comparable to bugs building up in a complex software system due to accumulated errors in the genetic code of human cells.
Fixing immune cells, such as T cells, could be an initial step in reversing ageing, as their function declines with age, leading to increased susceptibility to disease.
Errors in the genetic code can be reprogrammed using AI to read, rewrite, and reverse cells, or at least slow the ageing process.